Aligos Therapeutics (ALGS) vs GridAI Technologies (GRDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Aligos Therapeutics (ALGS) over the past year, gaining 20.0% versus a loss of 45.9%. Over five years, ALGS leads with a -98.7% price change compared with -100.0% for GRDX. GridAI Technologies is the larger company by market cap ($34.2 million vs $33.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | GRDX |
|---|---|---|
| Share price | $5.31 | $4.80 |
| Market cap | $33.16M | $34.23M |
| 1-day change | -0.19% | +16.50% |
| YTD return | -42.92% | +3.00% |
| 1-year return | -45.93% | +20.00% |
| 5-year return | -98.66% | -99.99% |
| EPS (TTM) | $-7.41 | $-5.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $6.93 |
| 52-week low | $3.98 | $1.87 |
| Distance from 52-week high | -61.21% | -30.73% |
| Analyst consensus | none | — |
| Avg. price target upside | +886.44% | — |
| Average volume | 91.45K | 101.84K |
| Shares outstanding | 5.44M | 7.13M |
| Employees | 82 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed ALGS by 65.9 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Healthcare · Biotechnology · 82 employees
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Healthcare · Biotechnology
ALGS vs GRDX FAQ
Which is bigger, Aligos Therapeutics or GridAI Technologies?
GridAI Technologies (GRDX) is larger, with a market capitalization of $34.23M compared with $33.16M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or GRDX?
GRDX returned +20.00% over the past 12 months, compared with -45.93% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and GridAI Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.